Escient Pharmaceuticals IPO

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Register for Details

For more details on financing and valuation of private companies similar to Escient Pharmaceuticals before its M&A, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Escient Pharmaceuticals

plusminus

Can you invest in Escient Pharmaceuticals pre-IPO?

You can no longer invest in Escient Pharmaceuticals with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell shares of Escient Pharmaceuticals before it goes public?

You can no longer sell shares of Escient Pharmaceuticals on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

What is the pre-IPO value of my Escient Pharmaceuticals shares?

Forge can no longer determine the value of Escient Pharmaceuticals shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Escient Pharmaceuticals a publicly traded company?

Escient Pharmaceuticals became a public company following its M&A on 04/23/2024 and is now a publicly traded company.
plusminus

Will Escient Pharmaceuticals go IPO?

Escient Pharmaceuticals became a public company following its M&A on 04/23/2024.
plusminus

What is Escient Pharmaceuticals’ IPO price?

The IPO price of Escient Pharmaceuticals is not currently available.
plusminus

When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2015.
plusminus

What is Escient Pharmaceuticals funding to date?

Escient Pharmaceuticals has raised $243.51MM to date.

Who are Escient Pharmaceuticals’s major investors?

Cowen Group
Perceptive Advisors
Redmile Group
Sanofi Genzyme BioVentures
Osage Partners
The Column Group
Altitude Life Science Ventures
NEA

Escient Pharmaceuticals Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
11/28/2022 Series C $120MM $xx.xx $256.49MM NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, Altitude Life Science Ventures
Price per Share
$xx.xx
Shares Outstanding
160,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, Altitude Life Science Ventures
09/14/2020 Series B $82.96MM $xx.xx $178.2MM Sanofi Ventures, Cowen Healthcare Investments, Redmile Group, Perceptive Advisors, The Column Group, 5AM Ventures, Osage University Partners
Price per Share
$xx.xx
Shares Outstanding
66,371,941
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sanofi Ventures, Cowen Healthcare Investments, Redmile Group, Perceptive Advisors, The Column Group, 5AM Ventures, Osage University Partners
05/09/2018 Series A $40.55MM $xx.xx $67.58MM The Column Group, 5AM Ventures, Osage University Partners
Price per Share
$xx.xx
Shares Outstanding
40,546,205
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
The Column Group, 5AM Ventures, Osage University Partners
Updated on: Nov 5, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.